FeStival
Research type
Research Study
Full title
Feasibility study of tissue and blood collection in oncogene-addicted and neoadjuvantly treated non-small cell lung cancer (NSCLC)
IRAS ID
336531
Contact name
Sanjay Popat
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
We are conducting a study to demonstrate the feasibility of collecting paired samples of blood and viable tissue in patients with metastatic lung cancer driven by genetic alterations (aka oncogene-addicted- Cohort 1), and patients with early-stage resectable lung cancer undergoing immunotherapy prior to planned surgery (i.e. neoadjuvant immunotherapy/checkpoint inhibitor therapy- Cohort 2). In the metastatic setting, benchmarking the proportion of patients who can provide paired samples is important as genetic analysis of viable tumour material allows personalisation of subsequent anti-cancer treatment. In the neoadjuvant setting, we hope to benchmark the proportion of patients who have viable tissue at the time of surgery post-immunotherapy, as this has only recently become a standard of care treatment strategy. Whilst the primary study aim is to demonstrate feasibility of collection of paired samples of blood and viable tissue in both these populations, secondary aims include reviewing the proportion of patients who have tissue that is feasible to sample at baseline/on progression and the proportion who are able to provide blood samples at all specified timepoints (some of which are additional to the standard of care), as well as to collect tissue and blood samples for future analyses and assess temporal evolution in these samples
REC name
London - Fulham Research Ethics Committee
REC reference
24/LO/0791
Date of REC Opinion
22 Jan 2025
REC opinion
Further Information Favourable Opinion